

A. Kowalska¹⁾, D. Gąsior-Perczak¹⁾, I. Pałyga¹⁾, T. Trybek¹⁾, A. Słuszniak²⁾

Is ultrasensitive Tg measurement capable of substituting for Tg measurement after rhTSH stimulation in evaluation of effectiveness of radioiodine ablation in patients with differentiated thyroid cancer

¹⁾Endocrinology Department, Holycross Cancer Centre, Kielce, Poland ²⁾Laboratory of Tumor Markers, Holycross Cancer Centre, Kielce, Poland

INTRODUCTION

Undetectable concentration of Tg after rhTSH stimulation (Tg/rhTSH) is one of the most important criteria in evaluating the effectiveness of radioiodine ablation in patients with differentiated thyroid cancer (DTC) treated with 131I

AIM

To evaluate the possibility of using Tg measurements during L-T4 (Tg/L-T4) treatment by the ultrasensitive method, instead of Tg measurements after rhTSH stimulation (Tg/rhTSH), in assessment of response to the initial treatment of DTC.

MATERIAL

The study was performed on 34 consecutive DTC patients after surgery and adjuvant treatment with 131I, referred for evaluation of ablation effectiveness 9 months after 131I treatment.


METHOD


Tg measurement was performed in patients during L-T4 treatment at 2 time points: before administration of rhTSH and 5 days after the first injection, using both tests:

Tg detection with CLIA (analytical sensitivity 0.2 ng/ml and functional sensitivity of 0.9 ng/ml)

and Tg by TRACE (analytical sensitivity of 0.09 ng/ml and functional sensitivity 0.15 ng/ml).

RESULTS Tg/





	PATIENT			
	1	2	3	4
Tg/rhTSH concentration after rhTSH administration (measured by CLIA assay) [ng/ml]	1.02	1.83	2.20	9.24
Tg/L-T4 concentration before rhTSH administration (measured by TRACE assay) [ng/ml]	0.09	0.1141	0.1629	0.09

CONCLUSIONS

- 1. None of the four cases with indeterminate response to ablation showed elevated Tg/L-T4 concentrations according to the ultrasensitive TRACE assay.
- 2. Results in our trial group do not entitle us to recommend determinations of Tg/L-T4 with the TRACE method instead of the Tg/rhTSH in assessing the ablation efficacy.
- 3. It is necessary to validate the method on a larger group of patients.

Thyroid Cancer 1

Aldona Kowalska

